Introduction
Recent advances in cardiovascular research have provided new insight into the processes involved in the pathogenesis of acute coronary syndromes (ACS). Extensive evidence implicates infl ammatory mediators in the development of atherogenesis. In addition, infl ammation appears to play a fundamental role in the pathogenesis of plaque rupture. Earlier studies suggested that local infl ammation results in rupture of a single vulnerable plaque, leading to coronary thrombosis. More recent evidence supported the emerging concept of the "vulnerable patient," suggesting that unstable coronary syndromes are associated with widespread infl ammatory activation of the coronary tree [1, 2] . Thus, both researchers and clinicians have turned to biochemical markers of infl ammation as possible noninvasive indicators of the risk of recurrent cardiovascular events following an ACS and as predictors of the success of therapeutic interventions [3] .
High-sensitivity C-reactive protein (hsCRP), the prototypical infl ammatory biomarker, seems to provide important prognostic information in ACS. In patients with unstable angina or non-Q-wave myocardial infarction enrolled in the Thrombolysis in Myocardial Infarction (TIMI) 11A trial [4] , elevated CRP at presentation correlated with 14-day mortality, even in patients with a negative rapid cardiac troponin T assay. In addition, persistent elevation of hsCRP 30 days following an ACS was associated with a signifi cantly increased 2-year mortality rate in the Aggrastat-to-Zocor (A to Z) trial [5•] . Patients treated with more aggressive statin therapy were more likely to achieve lower levels of hsCRP. However, although CRP is a reliable marker of infl ammation, several other immune and infl ammatory mediators are critically involved in the pathogenesis of ACS and may serve as new biomarkers, providing additional diagnostic and prognostic information. These novel molecular markers may serve as a window into the underlying pathophysiologic mechanisms of coronary atherothrombotic disease and may guide a more individualized treatment approach.
The Chemokines
The chemokines are a family of small chemotactic cytokines with molecular weights in the range of 8 to 14 kDa and a strikingly similar tertiary structure. There are approximately 50 human chemokines, which can be classifi ed into CC, CXC, C, or CX3C subfamilies based on the number of amino acids between the fi rst two of the four conserved cysteine residues that characterize chemokine structure. From a functional standpoint, chemokines can be divided broadly into two categories: 1) homeostatic chemokines that are constitutively expressed in certain tissues and may be responsible for basal leukocyte traffi cking and formation of the fundamental architecture of lymphoid organs, and 2) inducible chemokines that are strongly upregulated by infl ammatory or immune stimuli and actively participate in the infl ammatory reactions by inducing leukocyte recruitment [6] . Although this generalization has been challenged by studies demonstrating that certain chemokines felt to be homeostatic (such as SDF-1) [7] are inducible upon immune activation, it offers valuable insight into the role of members of the chemokine family in pathologic states. Extensive evidence suggests that both CC and CXC chemokines are induced in human atherosclerotic lesions and may play a role in atherogenesis and plaque destabilization.
Monocyte Chemoattractant Protein-1/CCL2: An Essential Mediator in the Pathogenesis of Atherosclerosis
Monocyte chemoattractant protein (MCP)-1, the most thoroughly characterized CC chemokine, was identifi ed as a monocyte-specifi c chemoattractant that was later demonstrated to attract T lymphocytes and natural killer cells but not neutrophils. Enhanced expression of MCP-1 was demonstrated in a variety of pathologic conditions associated with infl ammation and mononuclear cell infi ltration. Extensive experimental evidence suggests that MCP-1 is highly expressed in atherosclerotic plaques [8] and mediates macrophage recruitment in the atheromatous lesion (Fig. 1) . Fatty streaks, the hallmark of early atherosclerotic disease, are composed of lipid-laden macrophages termed foam cells. Oxidized lipids mediate foam cell formation and have long been implicated as important mediators of atherosclerosis. Minimally oxidized lowdensity lipoproteins (LDLs), but not native LDLs, induce MCP-1 production in vascular endothelial and smooth muscle cells [9] . MCP-1 is tethered to proteoglycans on Enhanced expression of MCP-1 in the vascular wall may contribute to progression of atherosclerotic disease through Fc activation, stimulation of smooth muscle cell (SMC) proliferation, and induction of plaque neovascularization. MCP-1 may also induce matrix metalloproteinase (MMP) synthesis, promoting matrix degradation and plaque disruption. It is also capable of upregulating tissue factor (TF) expression by exerting procoagulant effects (upper right). MCP-1 is also involved in infarct healing and cardiac remodeling. During the proinfl ammatory phase of healing, MCP-1 is upregulated in the infarcted myocardium and mediates Mo recruitment. As the infarct heals, MCP-1 synthesis is suppressed, leading to resolution of infl ammation and formation of a scar. Prolonged increase of plasma MCP-1 levels following acute coronary syndrome may identify patients exhibiting an enhanced infl ammatory response in the healing myocardium. Timely repression of MCP-1 synthesis is crucial for optimal healing; sustained infl ammation may result in extensive matrix degradation and adverse remodeling of the infarcted ventricle. EC-endothelial cell.
